Reaction Details | |||
---|---|---|---|
Report a problem with these data | |||
Target | Bcl-2-like protein 1 | ||
Ligand | BDBM209225 | ||
Substrate/Competitor | n/a | ||
Meas. Tech. | Time Resolved-Fluorescence Resonance Energy Transfer (TR-FRET) Assay | ||
Temperature | 298.15±n/a K | ||
Ki | <0.1±n/a nM | ||
Comments | extracted | ||
Citation | Wang, L; Doherty, G; Wang, X; Tao, Z; Bruncko, M; Kunzer, AR; Wendt, MD; Song, X; Frey, R; Hansen, TM; Sullivan, GM; Judd, A; Souers, A Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases US Patent US9266877 Publication Date 2/23/2016 | ||
More Info.: | Get all data from this article, Assay Method | ||
Bcl-2-like protein 1 | |||
Name: | Bcl-2-like protein 1 | ||
Synonyms: | Anti-apoptotic Bcl-2 protein | Apoptosis Regulator Bcl-xL | Apoptosis regulator Bcl-X | B2CL1_HUMAN | BCL2-like 1 isoform 1 | BCL2L | BCL2L1 | BCLX | Bcl-2-like protein 1 (Bcl-XL) | Bcl-X | Bcl-xL/Bcl-2-binding component 3 | Bcl2-L-1 | Bcl2-antagonist of cell death (BAD) | ||
Type: | Mitochondrion membrane; Single-pass membrane protein | ||
Mol. Mass.: | 26039.60 | ||
Organism: | Homo sapiens (Human) | ||
Description: | n/a | ||
Residue: | 233 | ||
Sequence: |
| ||
BDBM209225 | |||
n/a | |||
Name | BDBM209225 | ||
Synonyms: | US9266877, 171 | ||
Type | Small organic molecule | ||
Emp. Form. | C37H37N7O4S2 | ||
Mol. Mass. | 707.864 | ||
SMILES | Cc1[nH]c(C#N)c(CC2CCCCC2)c1-c1ccc(nc1C(=O)NS(C)(=O)=O)N1CCc2cccc(C(=O)Nc3nc4ccccc4s3)c2C1 |(7.93,2.6,;7.3,4.01,;8.07,5.35,;7.04,6.49,;7.36,8,;7.68,9.5,;5.63,5.86,;4.3,6.63,;4.3,8.17,;2.96,8.94,;2.96,10.48,;4.3,11.25,;5.63,10.48,;5.63,8.94,;5.79,4.33,;4.65,3.3,;5.42,1.97,;4.65,.63,;3.11,.63,;2.34,1.97,;3.11,3.3,;2.34,4.64,;.8,4.64,;3.11,5.97,;2.34,7.3,;1.57,8.64,;1,6.53,;3.67,8.07,;2.34,-.7,;.8,-.7,;.03,-2.03,;.8,-3.37,;.03,-4.7,;.8,-6.03,;2.34,-6.03,;3.11,-4.7,;4.65,-4.7,;5.42,-3.37,;5.42,-6.03,;6.96,-6.03,;7.86,-4.79,;9.33,-5.26,;10.66,-4.49,;12,-5.26,;12,-6.8,;10.66,-7.57,;9.33,-6.8,;7.86,-7.28,;2.34,-3.37,;3.11,-2.03,)| | ||
Structure |